SYnAbs and Univercells announce success on anti-biosimilar antibody assay


SYnAbs and Univercells, two neighboring companies based in Gosselies, Belgium, today announce service deal success. Under the terms of the agreement, SYnAbs developed an anti-drug antibody (ADA) immuno-assay to measure features of a biosimilar monoclonal antibody developed by Univercells.


Univercells is a technology company delivering novel biomanufacturing platforms, aiming at making biologics available & affordable to all. They’ve delivered a biosimilar version of a blockbuster monoclonal antibody and like to attest batch-to-batch variability and to confirm its biosimilarity compared to the original version.


Thanks to its anti-idiotype monoclonal antibody generation expertise, SYnAbs has developed a custom ELISA. The format of the immuno-assay will be sandwich-type enzyme immunoassay ELISA in which the biosimilar binds to the antigen on the microtiter plate and a biotinylated anti-idiotype antibody recognizes the complex. 


SYnAbs has determined the best conditions for the antibody pair and optimized the different features of the assay, including but not limited to, the best suited ELISA plate, coating conditions, denaturing agents, antigen and antibody concentrations, and incubation time.


At the end of the process, SYnAbs has performed a bioassay efficacy testing in order to check the antibody activity on cells through EC50 measurement.